Study of Patient Eligibility for Participation in Surgery Clinical Trials - Full Text View

Sponsored by:	National Cancer Institute (NCI)
Information provided by:	National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:	NCT00019799

Purpose

RATIONALE: Evaluating patients for eligibility in clinical trials may help doctors plan more effective surgical treatment for patients who have cancer.

PURPOSE: This clinical trial is studying patients to determine if they are eligible for surgery clinical trials.

Condition	Intervention
Unspecified Adult Solid Tumor, Protocol Specific	Procedure: physiologic testing

MedlinePlus related topics: Cancer

U.S. FDA Resources

Study Type:

Interventional

Study Design:

Screening

Official Title:

Evaluation for NCI Surgery Branch Clinical Research Protocols

Further study details as provided by National Cancer Institute (NCI):

Estimated Enrollment:

5000

Study Start Date:

August 1999

Detailed Description:

OBJECTIVES:

Evaluate patient eligibility for participation in NCI Surgery Branch protocols.
Permit standard therapy for patients ineligible for active Surgery Branch protocols who present novel or unique clinical training opportunity or conditions requiring immediate intervention in order to avoid compromising patient's health.

OUTLINE: Patients undergo various diagnostic procedures and clinical testing to determine protocol eligibility. The testing and procedures may include HLA blood typing, hepatitis screen, HIV serology, fine-needle aspiration, open incisional or excisional biopsies, leukapheresis, arteriogram, laparoscopy, various nuclear medicine and imaging scans with or without contrast dye, or pulmonary function tests.

PROJECTED ACCRUAL: A total of 5,000 patients will be accrued for this study within 5 years.

Eligibility

Ages Eligible for Study:

16 Years and older

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

No

Criteria

DISEASE CHARACTERISTICS:

Biopsy proven or suspected malignant disease

PATIENT CHARACTERISTICS:

Age:

16 and over

Performance status:

Not specified

Life expectancy:

Not specified

Hematopoietic:

Not specified

Hepatic:

Not specified

Renal:

Not specified

PRIOR CONCURRENT THERAPY:

Biologic therapy

Not specified

Chemotherapy

Not specified

Endocrine therapy

Not specified

Radiotherapy

Not specified

Surgery

Not specified

Other

No concurrent therapy unless ineligible for Surgery Branch protocol and standard therapy deemed to be in best interest of patient and suitable for training needs of Surgery Branch staff

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00019799

Locations

United States, Maryland
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office	Recruiting
Bethesda, Maryland, United States, 20892-1182
Contact: Clinical Trials Office - Warren Grant Magnusen Clinical Center 888-NCI-1937

Sponsors and Collaborators

National Cancer Institute (NCI)

Investigators

Study Chair:

Steven A. Rosenberg, MD, PhD

NCI - Surgery Branch

More Information

Clinical trial summary from the National Cancer Institute's PDQ® database This link exits the ClinicalTrials.gov site